at Benzinga.com (Dec 30, 2014)
Data from clinical trials of Provenge appears to have been analyzed differently by researchers...
Data from clinical trials of Provenge appears to have been analyzed differently by researchers than how Dendreon (DNDN +0.2%) told the FDA it would be. DNDN had originally said the data would be analyzed by age, using a cut-point of 65, but when the report was published its stated age was 71. The company says the discrepancy is immaterial and that Provenge is safe and effective. The FDA also stands by its decision to approve the treatment.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Nov 18, 2014)
at Zacks.com (Nov 11, 2014)
at CNBC.com (Nov 10, 2014)
at Zacks.com (Nov 10, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs